Condition 1: Diabetes Mellitus type 2. Condition 2: Coronary artery disease. Type 2 diabetes mellitus Atherosclerotic heart disease of native coronary artery
Conditions
Interventions
Intervention 1: Intervention group: The 50 patients in the intervention group will be treated with Empagliflozine 10 mg daily for 6 months (made by Abidi Pharmaceutical Company). Intervention 2: Contr
Sponsors
Zanjan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: Age between 40-75 year-old HbA1c between 6.5 to 9 Diabetes mellitus type 2 Under fix continues treatment for at least 3 month BMI less than 40 Fixed Diet and physical activity
Exclusion criteria
Exclusion criteria: Pregnancy Heart Failure (NYHA class 3-4) History of allergic reaction to SGLT2 inhibitors Drugs History of SGLT2 inhibitor Drugs usage GFR3 times upper normal limit Presence of urinary-genital infection History of infection less than 1 month prior to the study History of Anti-inflammatory drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes hs-Troponin-I. Timepoint: At the begining of the study, befor the intervention and 6 month after the intervention. Method of measurement: Laboratory Measurments.;Changes in level of hs-CRP. Timepoint: At the begining of the study, befor the intervention and 6 month after the intervention. Method of measurement: Laboratory Measurments.;Changes in level of lipid profile. Timepoint: At the begining of the study, befor the intervention and 6 month after the intervention. Method of measurement: Laboratory Measurments. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHoma Taheri
Zanjan University of Medical Sciences
Outcome results
None listed